Your browser doesn't support javascript.
loading
Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.
Haas, Sylvia; Ten Cate, Hugo; Accetta, Gabriele; Angchaisuksiri, Pantep; Bassand, Jean-Pierre; Camm, A John; Corbalan, Ramon; Darius, Harald; Fitzmaurice, David A; Goldhaber, Samuel Z; Goto, Shinya; Jacobson, Barry; Kayani, Gloria; Mantovani, Lorenzo G; Misselwitz, Frank; Pieper, Karen; Schellong, Sebastian M; Stepinska, Janina; Turpie, Alexander G G; van Eickels, Martin; Kakkar, Ajay K.
Afiliação
  • Haas S; Formerly Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Ten Cate H; Department of Internal Medicine, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.
  • Accetta G; Thrombosis Research Institute, London, United Kingdom.
  • Angchaisuksiri P; Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Bassand JP; Thrombosis Research Institute, London, United Kingdom.
  • Camm AJ; Department of Cardiology, EA 3920, University of Besançon, Besançon, France.
  • Corbalan R; Division of Cardiovascular Sciences, St George's University of London, London, United Kingdom.
  • Darius H; Department of Cardiology, Catholic University School of Medicine, Santiago, Chile.
  • Fitzmaurice DA; Department of Cardiology, Vascular Medicine and Intensive Care Medicine, Vivantes Neukoelln Medical Centre, Berlin, Germany.
  • Goldhaber SZ; Department of Primary Care Clinical Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
  • Goto S; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States of America.
  • Jacobson B; Department of Medicine (Cardiology), Tokai University School of Medicine, Isehara, Japan.
  • Kayani G; Department of Hematology and Molecular Medicine, Johannesburg Hospital, University of the Witwatersrand, Johannesburg, South Africa.
  • Mantovani LG; Thrombosis Research Institute, London, United Kingdom.
  • Misselwitz F; Center for Public Health Research (CESP), University of Milano-Bicocca, Milan, Italy.
  • Pieper K; Bayer Pharma AG, Berlin, Germany.
  • Schellong SM; Duke Clinical Research Institute, Durham, NC, United States of America.
  • Stepinska J; Internal Medicine, Dresden-Friedrichstadt Hospital, Dresden, Germany.
  • Turpie AG; Intensive Cardiac Therapy Clinic, Institute of Cardiology, Warsaw, Poland.
  • van Eickels M; Department of Medicine, McMaster University, Hamilton, Canada.
  • Kakkar AK; Bayer Pharma AG, Berlin, Germany.
PLoS One ; 11(10): e0164076, 2016.
Article em En | MEDLINE | ID: mdl-27792741
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Vitamina K / Anticoagulantes Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Vitamina K / Anticoagulantes Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Ano de publicação: 2016 Tipo de documento: Article